# Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1

*PRI Rank #6 · Topics and Trends in Most Cited Growth Hormone and Insulin-like Growth Factors Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/growth-hormone-and-insulin-like-growth-factors/2026/rank-6*

| Field | Value |
| --- | --- |
| Rank | #6 |
| 18m citations | 20 |
| Journal | The Journal of Clinical Endocrinology & Metabolism |
| Year | 2024 |
| DOI | 10.1210/clinem/dgae707 |
| Corresponding authors | Fredrik Tiberg |
| Institution | IRCCS Ospedale Policlinico San Martino, Italy |

**Ranking page:** [Topics and Trends in Most Cited Growth Hormone and Insulin-like Growth Factors Papers, Class of 2026](https://pri.pepkio.com/top-papers/growth-hormone-and-insulin-like-growth-factors/2026)

**Paper link:** [10.1210/clinem/dgae707](https://doi.org/10.1210/clinem/dgae707)

## Topics

acromegaly · Octreotide · CAM2029 · subcutaneous depot · FluidCrystal technology · Insulin-like growth factor 1 · growth hormone · biochemical control · Octreotide · Lanreotide · self-administration · quality of life · treatment satisfaction · Randomized double-blind placebo-controlled trial · dose reduction

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Growth Hormone and Insulin-like Growth Factors Papers, Class of 2026. https://pri.pepkio.com/top-papers/growth-hormone-and-insulin-like-growth-factors/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```